NCT06817174Recruiting
Ovarian Cancer Radiomics Approach in CT Led Evaluation
Prospective Validation of CT Based Radiomic Models to Predict Surgical and Clinical Outcomes in Advanced Epithelial Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment. There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer. This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 168 (estimated)
- First submitted
- 4 Feb 2025
- Start date
- 10 Feb 2025
- Primary completion date
- Jan 2032
- Lead sponsor
- Imperial College Healthcare NHS Trust
- Diseases
- Ovarian cancer
- NCT number
- NCT06817174
What you commit to
- Study type: Observational
- Planned participants: 168
- From 10 Feb 2025 to the primary completion date, Jan 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgery for resection of an adnexal mass;
Other illness
- Known contra-indication to CT with IV contrast (e.g. contrast allergy, renal failure, inability to lie flat);
- No visible disease \<2cm on portal venous phase baseline CT scan;
- Significant artefact on CT image for example from metal prostheses that precluded meaningful segmentation of visible disease
Other
- Unable to give informed consent;
- Known pregnancy;
- Only fit for palliative care at initial presentation
Who the study is looking for
- Written (signed and dated) informed consent
- Age 18 years or over
- Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)
- Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery
- Evaluable baseline portal venous phase CT scan prior to surgical or medical treatment for ovarian cancer
- Disease visible on pre-treatment portal venous phase baseline CT scan (≥2cm)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Imperial College NHS Healthcare Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.